KRAS combo data prompts Revolution Medicines toward Phase 3
Revolution Medicines revealed early data for a two-KRAS inhibitor drug combination, including Daraxonrasib, and plans a Phase 3 trial, signaling potential progress in targeting KRAS-driven cancers.